Shamburg News · 8-K filed Nov 12, 2026, 4:10 PM EST
Equillium Reports Third Quarter 2026 Financial Results and EQ504 Clinical Progress
EQ · Equillium, Inc.
- Earnings
- Financing
- Other event
- Materiality: high
Equillium reported financial results for the third quarter ended September 30, 2026, with a net loss of $4.6 million, or $(0.04) per basic and diluted share, compared with a net loss of $4.2 million, or $(0.06) per share, a year earlier. Cash and cash equivalents totaled $53.3 million as of September 30, 2026, and the company reported a pro forma balance of approximately $72.0 million after a second tranche of about $20 million in private placement proceeds closed in October 2026. The company said it initiated a Phase 1 trial of EQ504 and expects topline proof-of-mechanism data in the second quarter of 2027, with cash expected to fund operations into 2029.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458379.
Written from the filing by Shamburg Markets. Figures are as reported by the company.